Not sure where to start? Get matched →
All of CJC-1295 / Ipamorelin (Injectable)
CJC-1295 / Ipamorelin (Injectable) in New Jersey — pepti Pen
Popular
New Jersey

CJC-1295 / Ipamorelin (Injectable) in New Jersey

Doctor-prescribed CJC-1295 / Ipamorelin (Injectable) for New Jersey residents. Reviewed by licensed New Jersey physicians, compounded at FDA-registered pharmacies, and shipped to your door.

The pepti Pen cartridge for this treatment is sold out right now. The vial is the same medication at our best price.

All-in monthly price

$239

No membership fee · this is the full price · free shipping · avg 4-week supply

Medication, provider care, labs & dose adjustments — all in one price.
~28-day supply. Your provider sets your exact dose, so yours may vary — your refill arrives as you finish the last one.
Start assessment

Add in-depth bloodwork

Optional — add a physician-reviewed at-home blood panel to your plan.

At-home kit (1 device)+$149

Your sex-hormone baseline plus the safety markers that matter on therapy — blood counts, liver and kidney function — from one painless upper-arm device. Matched to your sex (PSA for men; progesterone & FSH for women). No needle, no clinic, physician-reviewed.

Money-back guarantee
Free AI care assistant
HSA/FSA accepted
Cancel anytime
Free shipping

This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.

Dr. Gene
Physician Reviewed

Reviewed by Dr. Gene, MD · Board-certified Family Medicine

Every Pepti prescription is reviewed by a licensed U.S. physician before it's dispensed — and only provided if clinically appropriate.

The process

How it works in New Jersey

  1. 1Complete a free online intake (~5 minutes).
  2. 2A licensed New Jersey physician reviews your case within 24 hours.
  3. 3Your prescription ships from our FDA-registered compounding pharmacy.
  4. 4Free shipping arrives 2–4 business days later. Refills ship automatically when your supply runs out — cancel anytime.
The treatment

What CJC-1295 / Ipamorelin (Injectable) does

Growth hormone releasing combo that promotes deep sleep, recovery, and cellular regeneration.

✓Better sleep
✓Anti-aging
✓Muscle recovery
✓Body composition
Formulation
Injectable vial5 mL
CJC-12956 mg
Ipamorelin12 mg
Pepti Pen cartridge3 mL cartridge (300 units)
CJC-12951.5 mg
Ipamorelin6 mg

Amounts shown are per unit. Compounded fresh at a US FDA-registered pharmacy.

Quality

Every batch independently tested

Every medication batch dispensed through Pepti is independently tested by a qualified third-party laboratory for applicable quality and safety standards before the pharmacy releases it. Batches are tested to the same standard used by 503B outsourcing facilities.

Sterility

USP <71>

Confirms the finished preparation is free of viable microorganisms.

Bacterial endotoxins

USP <85>

Screens for endotoxins that can cause fever or inflammatory reactions.

Potency

Assay

Verifies the labeled concentration of the active peptide is what is in the vial.

Purity

HPLC

Checks the active peptide against impurities and degradation products.

Identity

Mass spectrometry

Confirms the peptide in the vial is the correct molecule.

pH

USP <791>

Confirms the solution sits within the range specified for injection.

Particulate matter

USP <788>

Checks the finished vial for visible and sub-visible particles.

Container closure integrity

USP <1207>

Confirms the vial seal holds so sterility is maintained through the beyond-use date.

Compounded by licensed U.S. pharmacies. Prescribed by licensed medical providers. Shipped directly to patients in New Jersey.Documentation available upon request →View lab results by lot →
New Jersey

Telemedicine in New Jersey.

New Jersey permits telemedicine prescribing under the New Jersey telemedicine statute and Board of Medical Examiners rules. A New Jersey-licensed physician can establish the patient relationship through online intake review. Pepti is available in all 50 states and Washington, D.C.

New Jersey sits inside the New York metro market, with highly informed patients who frequently pair peptide therapy with existing primary care.

New Jersey cities Pepti serves

Pepti delivers CJC-1295 / Ipamorelin (Injectable) to patients across New Jersey, including Newark, Jersey City, Paterson, Elizabeth, Edison, Trenton, Clifton, Camden, Bayonne, East Orange, Passaic, Union City
+ 27 more cities, Vineland, Hoboken, New Brunswick, Perth Amboy, Plainfield, West New York, Hackensack, Sayreville, Linden, Fort Lee, Kearny, Atlantic City, Fair Lawn, Long Branch, Garfield, Westfield, Princeton, Rahway, Englewood, Bergenfield, Millville, Bridgeton, Paramus, Ridgewood, Lodi, Cliffside Park, Carteret
. All shipments use the same FDA-registered compounding pharmacy regardless of city.

Your protocol

How CJC-1295 / Ipamorelin is prescribed in New Jersey.

Who it's for

  • Adults seeking growth-hormone support through the body's own pulsatile release
  • Patients focused on sleep quality, recovery, and body composition
  • People who want a gentler growth-hormone peptide than tesamorelin

Your physician decides whether CJC-1295 / Ipamorelin is appropriate for you after reviewing your intake and labs.

Directions & duration

Inject 0.25 mL (25 units) subcutaneously once daily Monday through Friday on an empty stomach.

Cycle. Ongoing nightly treatment. Refills ship monthly and your physician adjusts the dose as you go.
Ready for more? When you're ready for more, ask your physician to double your dose. If approved, the extra vial is billed at cost and applied to your next fill.
Directions shown are the pharmacy's standard for this preparation. Your prescription label is the final word.

What's included

  • Licensed physician review of your intake, history, and labs
  • Medication compounded to your prescription by a PCAB-accredited, FDA-registered pharmacy
  • Every batch independently tested before release
  • Sterile syringes and alcohol prep pads for injectables
  • Tracked delivery to your door, refills on schedule
  • Message your physician anytime; dose changes without an appointment

Storage & handling

  • Store refrigerated (36–46°F / 2–8°C) at all times, including before first use.
  • One vial is your monthly supply. A fresh vial ships to your New Jersey address every 28 days on your refill schedule, so you're always well inside the beyond-use date on your label.
  • Protect from light. Wipe the stopper with an alcohol pad before every draw.
  • Dispose of syringes in the sharps container per the included instructions.

What to expect

A typical course of CJC-1295 / Ipamorelin in New Jersey.

TimeframeWhat patients commonly report
Weeks 1–3Many patients first notice deeper sleep and easier recovery from workouts.
Weeks 4–8Improved energy and body composition changes often become noticeable, especially with training and adequate protein.
Weeks 9–15 and onEffects tend to be cumulative and build with continued use. Your physician adjusts the dose over time and refills ship on schedule.
Individual results vary. Compounded medications are not FDA-approved; a licensed physician determines whether treatment is appropriate and monitors your progress.

The science

How CJC-1295 / Ipamorelin works, and what the research shows.

How it works

CJC-1295 is a GHRH analog that extends growth hormone release duration.

Ipamorelin is a selective GH secretagogue that triggers clean GH pulses without raising cortisol or prolactin.

Together they produce sustained, physiological GH elevation.

Clinical evidence

  • In a placebo-controlled study in healthy adults, single doses of CJC-1295 raised growth hormone output and IGF-1 for six or more days.

    Teichman et al., J Clin Endocrinol Metab 2006
  • Ipamorelin was characterized as the first selective ghrelin-receptor agonist — stimulating GH release without meaningful cortisol or prolactin elevation.

    Raun et al., Eur J Endocrinol 1998
  • The combination is a standard pairing in GH-peptide practice, though long-term outcome trials of the combo itself have not been conducted.

Full references with PubMed links are listed further down the page.

References

  1. Teichman SL, Neale A, Lawrence B et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · J Clin Endocrinol Metab (2006) · PMID 16352683
  2. Raun K, Hansen BS, Johansen NL et al.. Ipamorelin, the first selective growth hormone secretagogue · Eur J Endocrinol (1998) · PMID 9849822
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog · J Clin Endocrinol Metab (2006) · PMID 17018654
  4. Alba M, Fintini D, Sagazio A et al.. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse · Am J Physiol Endocrinol Metab (2006) · PMID 16822960
  5. Gobburu JV, Agersø H, Jusko WJ et al.. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers · Pharm Res (1999) · PMID 10496658
  6. Johansen PB, Nowak J, Skjaerbaek C et al.. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats · Growth Horm IGF Res (1999) · PMID 10373343
  7. Svensson J, Lall S, Dickson SL et al.. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats · J Endocrinol (2000) · PMID 10828840
  8. Venkova K, Mann W, Nelson R et al.. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus · J Pharmacol Exp Ther (2009) · PMID 19289567
  9. Beck DE, Sweeney WB, McCarter MD et al.. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients · Int J Colorectal Dis (2014) · PMID 25331030
  10. Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men · JAMA (2000) · PMID 10938176
  11. Blackman MR, Sorkin JD, Münzer T et al.. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial · JAMA (2002) · PMID 12425705
  12. Giannoulis MG, Sonksen PH, Umpleby M et al.. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial · J Clin Endocrinol Metab (2006) · PMID 16332938
  13. Nackeeran S, Kohn T, Gonzalez D et al.. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials · J Urol (2022) · PMID 34445892
  14. Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men · Am J Physiol Endocrinol Metab (2009) · PMID 19240251
  15. Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human · Ann Pediatr Endocrinol Metab (2017) · PMID 29025199
  16. Jetté L, Léger R, Thibaudeau K et al.. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog · Endocrinology (2005) · PMID 15817669
  17. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects · Growth Horm IGF Res (2009) · PMID 19386527
  18. Yuen KCJ, Biller BMK, Radovick S, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care · Endocrine Practice (2019) · PMID 31760824
  19. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays · Clin Chem (2011) · PMID 21285256
  20. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues · Sex Med Rev (2018) · PMID 28400207
  21. Renehan AG, Zwahlen M, Minder C et al.. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis · Lancet (2004) · PMID 15110491
  22. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B. Systematic review: the safety and efficacy of growth hormone in the healthy elderly · Annals of Internal Medicine (2007) · PMID 17227934
  23. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M et al.. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans · Sci Transl Med (2011) · PMID 21325617
  24. Grunstein RR, Handelsman DJ, Lawrence SJ et al.. Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy · J Clin Endocrinol Metab (1989) · PMID 2493027
  25. Harman SM, Metter EJ, Tobin JD et al.. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging · J Clin Endocrinol Metab (2001) · PMID 11158037
  26. Wu FC, Tajar A, Beynon JM et al.. Identification of late-onset hypogonadism in middle-aged and elderly men · N Engl J Med (2010) · PMID 20554979
  27. Liu H, Bravata DM, Olkin I et al.. Systematic review: the effects of growth hormone on athletic performance · Ann Intern Med (2008) · PMID 18347346
  28. Meinhardt U, Nelson AE, Hansen JL et al.. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial · Ann Intern Med (2010) · PMID 20439575
  29. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis · Sleep (1998) · PMID 9779515

Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.

Pharmacy network accreditation

PCAB-accredited pharmacies on every order.

Every fulfillment runs through a PCAB-accredited pharmacy.

See the lab results
PCAB — Pharmacy Compounding Accreditation Board · Accredited
  • Rigorous third-party quality & safety inspections
  • Cleanliness and sterile processes
  • Proper ingredient sourcing
  • Accurate dosing and formulation
  • Staff training and procedures
  • Accredited by NABP & ACHC
Common questions

Frequently asked
about CJC-1295 / Ipamorelin (Injectable) in New Jersey.

Yes. CJC-1295 / Ipamorelin (Injectable) is legal when prescribed by a physician licensed in New Jersey and dispensed by an FDA-registered compounding pharmacy. New Jersey permits telemedicine prescribing under the New Jersey telemedicine statute and Board of Medical Examiners rules. A New Jersey-licensed physician can establish the patient relationship through online intake review.

33 more questions about Pepti, answered.

Pepti serves all of New Jersey. A physician licensed in New Jersey reviews every order within 4 hours, the prescription is compounded by a state-licensed, FDA-registered pharmacy, and it ships free and tracked to any New Jersey street address. The price is the same as every other state.

Pepti operates in New Jersey through licensed physician partnerships. Compounded medications are produced at FDA-registered 503A pharmacies. Treatment decisions are made by your prescribing physician.